A Nurix Therapeutics director sold over 22,000 shares worth about $528,442 amid progress in the company's lead cancer drug, bexobrutideg, now in a Phase 3 trial for chronic lymphocytic leukemia. The trial marks a key development step with potential for accelerated approval. Nurix also reported strong financial results with adjusted earnings of $4.73 per share and revenue growth to $673 million, supported by $1.1 billion in cash, including a $700 million upfront payment from Roche. These factors position Nurix well for future growth and drug development through 2029.
Nurix Therapeutics director sold over 22,000 shares worth about $528,442 amid progress in a Phase 3 cancer drug trial. For readers following health-sector stocks, here is Pluang's market snapshot as of Oct 15, 2026 19:31 WIB: out of 150 priced US health-sector stocks, 95 rose and 46 fell. Notable movers include AbCellera Biologics Inc (ABCL) at USD 11.83 with a 1-day change of -4.37% and Pluang order activity showing 98% Sell, 10X Genomics Inc (TXG) at USD 70.00 with a 1-day change of -4.24% and 83% Sell activity, and Ascendis Pharma A/S (ASND) at USD 219.09 with a 1-day change of -3.48% and 100% Sell activity.
TiDB, powered by PingCAP, announced new cloud platform capabilities to support enterprise and AI applications on a unified data foundation. Key updates include the upcoming general availability of TiDB Cloud Premium, public previews of Bring Your Own...
The Saudi Arabia Non-Invasive Prenatal Testing (NIPT) market is projected to grow from $52.5 million in 2025 to $162.16 million by 2034, at a CAGR of 13.35%. Growth is fueled by rising maternal age, advances in molecular diagnostics, and increased he...
ONEOK completed a $4.425 billion acquisition of Brazos Midstream's natural gas assets, doubling its processing capacity in the Permian Midland Basin to about 2.3 billion cubic feet per day. The deal secures 600,000 acres under long-term contracts, st...
Charles Schwab reported Q3 earnings per share of $1.69, beating estimates despite slightly missing revenue forecasts with $7.17 billion. The quarter marked a 17% revenue increase year-over-year and a 23% rise in net income to $2.91 billion, driven by...
Alcoa will release its Q3 2026 earnings on October 15, with analysts divided on earnings per share and revenue forecasts due to factors like rising aluminum sales, inventory changes, and higher input costs. The company expects a 54.9% jump in aluminu...
